Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.
ABT - Abbott Laboratories
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$121.25
DETAILS
HIGH:
$145.00
LOW:
$92.00
MEDIAN:
$120.50
CONSENSUS:
$121.25
UPSIDE:
31.63%
Stock News
Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio
These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential
Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, nutrition, and generic medicines. Intuitive Surgical maintains a dominant position in robotic-assisted surgery with a high-margin, recurring revenue business model.
Here Are Wednesday's Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More
Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index's best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the tech-heavy index's best quarterly finish since 2020.
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks beating growth stocks.
3 No-Brainer Dividend Stocks to Buy Right Now
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
How Abbott's Largest Segment Is Preparing for the Next Growth Phase
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed a baby formula facility where potentially deadly bacteria were discovered and suspected of causing infant deaths, and instead opted for civil penalties, the Wall Street Journal reported on Sunday, citing people familiar with the matter.
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria was discovered and suspected of causing infant deaths, worsening a national shortage.
Price Targets
Abbott price target lowered to $112 from $120 at Evercore ISI
$112.00
(was $93.64)
Vijay Kumar
·
Evercore ISI
Abbott initiated with an Outperform at Baird
$121.00
(was $90.68)
David Rescott
·
Robert W. Baird
Abbott downgraded to Neutral from Outperform at Daiwa
$92.00
(was $92.75)
Daiwa
Abbott price target lowered to $143 from $144 at Barclays
$143.00
(was $96.83)
Matt Miksic
·
Barclays
Abbott price target lowered to $115 from $132 at Oppenheimer
$115.00
(was $95.46)
UBS
Abbott price target lowered to $115 from $135 at Piper Sandler
$115.00
(was $95.46)
Piper Sandler
Abbott price target lowered to $120 from $145 at Stifel
$120.00
(was $95.46)
Stifel Nicolaus
UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability
$158.00
(was $108.42)
Danielle Antalffy
·
UBS
Abbott Labs (ABT) Reiterated at Buy by Benchmark After FreeDM Trial Results
$145.00
(was $108.14)
New Street
Abbott price target lowered to $142 from $169 at Barclays
$142.00
(was $109.30)
Barclays
Freedom Capital Markets Upgrades Abbott Labs (ABT) to Buy
$120.00
(was $106.09)
Ilya Zubkov
·
Loop Capital Markets
Abbott price target lowered to $138 from $144 at Evercore ISI
$138.00
(was $108.61)
Evercore ISI
Abbott price target lowered to $132 from $140 at Oppenheimer
$132.00
(was $108.60)
UBS
Abbott price target lowered to $125 from $140 at Mizuho
$125.00
(was $108.60)
Anthony Petrone
·
Mizuho Securities
Abbott price target lowered to $135 from $150 at Piper Sandler
$135.00
(was $108.60)
Piper Sandler
Abbott price target lowered to $125 from $154 at Bernstein
$125.00
(was $108.60)
Bernstein
Abbott price target lowered to $122 from $146 at Wells Fargo
$122.00
(was $108.60)
Larry Biegelsen
·
Wells Fargo
Abbott price target raised to $154 from $150 at Bernstein
$154.00
(was $126.18)
Lee Hambright
·
Bernstein
Abbott price target lowered to $152 from $157 at Goldman Sachs
$152.00
(was $126.18)
Goldman Sachs
Abbott price target raised to $144 from $142 at Evercore ISI
$144.00
(was $123.97)
Evercore ISI